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Abstract
Coexpression of the macrophage colony-stimulating factor (CSF-1) and its receptor (CSF-1R) in metastatic ovarian
cancer specimens is a predictor of poor outcome in epithelial ovarian cancer. This suggests that an autocrine loop
is produced by which ovarian tumors can secrete CSF-1 stimulating the CSF-1R resulting in a more aggressive
phenotype. Our current work sought to validate this autocrine stimulation model using stable transfection of a
4-kb CSF-1 construct into otherwise nonvirulent Bix3 ovarian cancer cells. A representative clone, Bix3T8.2, pro-
duced a 72-fold increase in CSF-1 gene transcription rate (by nuclear run-off assays) and a 57-fold increase in
secreted CSF-1 protein (by sandwich ELISA), compared to parent cells. Comparison of Bix3T8.2 invasion, adhe-
sion, and motility in vitro and metastasis in vivo were made to parental and transfectant controls. Up to 12-fold
higher invasiveness was seen with Bix3T8.2 and 2- and 6-fold higher adhesion and motility, respectively, over con-
trols in vitro. In nude mice, i.p. injection of Bix3T8.2 produced a wide array of visceral, nodal, and distant metastasis
with a degree of enhanced tumor burden not seen in any of the 10 mice inoculated with transfectant control cells.
Complete absence of tumor take distinguished 40% of mice implanted with transfectant control cells. Disruption
of this autocrine loop using antisense oligomer therapy against CSF-1R and 3′ untranslated region knockdown of
CSF-1 protein resulted in reversal of in vitro and in vivo tumor phenotypes. This CSF-1 feedback loop offers a model
by which novel biologic therapies can potentially target multiple levels of this pathway.
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Introduction
Coexpression of the macrophage colony-stimulating factor (CSF-1)
and its receptor (CSF-1R encoded by the proto-oncogene c-fms)
has been shown to be a predictor of poor outcome in epithelial ovar-
ian cancer [1]. Clinical specimens from ovarian cancer metastases
display strong immunostaining for both CSF-1 and its receptor in
contrast to noninvasive borderline tumors, which do not coexpress
the CSF-1R/CSF-1, and to benign ovarian tissue, which expresses little
to no CSF-1R/CSF-1 [1–3]. At initial clinical presentation, elevated
levels of CSF-1 in both serum and ascitic fluid have been correlated
Abbreviations: CSF-1, macrophage colony-stimulating factor; CSF-1R, CSF-1 receptor;
uPA, urokinase-type plasminogen activator; ELISA, enzyme-linked immunosorbent
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with poor outcome in these patients with invasive ovarian carcinoma
[4,5]. In addition, serum CSF-1 levels have been demonstrated to be a
clinically useful correlate to ongoing disease status [6,7].
Given the prognostic value of this secreted form of CSF-1 in the
setting of ovarian cancer progression, an in vitro model that charac-
terizes the role of secreted CSF-1 can serve as proof of concept that
secreted CSF-1 promotes the activity of ovarian tumor cells. Reitera-
tion of the autocrine loop between the CSF-1 ligand and its receptor
provides an experimental model in which the mechanism of ovarian
cancer invasion and metastasis can be elucidated. Although the CSF-1
mRNA transcript produces several alternatively spliced products [8],
by far the major secreted form of CSF-1 that is found in ascites and
serum is encoded by a 4-kb transcript including a 2-kb 3′ untranslated
region (UTR). This transcript is regulated posttranscriptionally and
is stabilized by mRNA binding proteins (such as glyceraldehyde
3-phosphate dehydrogenase (GAPDH)) making this 4-kb transcript
with its AU-rich 3′UTR the most biologically relevant of the tran-
scripts [9,28].
The ability of ovarian cancer cells to invade a reconstituted base-
ment membrane has been shown to be stimulated by CSF-1 [10]. This
stimulation of invasion by the exogenous treatment of ovarian cancer
cells seems to be mediated through the actions of the urokinase-type
plasminogen activator (uPA) [10]. Urokinase is a serine protease in-
volved in tissue remodeling and, like CSF-1, has been found to be
present in elevated levels in many cancers, including those of the breast
and ovary, where it is associated with a poor prognosis [11,12]. In
our study [11], there was a significant association between ovarian
tumors, which coexpress CSF-1/CSF-1R, and those, which coexpress
uPA/uPAR. It follows from the clinical correlation of CSF-1 to meta-
static progression that uPA is one of the downstream mediators of
CSF-1–related tumor behavior.
In the current work, we present the transformation of ovarian can-
cer cells isolated from ascites by the stable overexpression of the
4-kb CSF-1 and study the effect on phenotypic tumor characteristics
both in vitro and in vivo. While characterizing the effect of CSF-1 in
these cells, designs for therapeutic targets are also evaluated, which
may provide insight into the etiologic role of CSF-1 and the process
by which endogenous secretion through overexpression produces an




The human ovarian cancer parental cell line Bix3, which is known
to secrete relatively low CSF-1 [2,10], was maintained in Dulbecco’s
modified Eagle’s medium–F-12 Ham’s medium supplemented with
1% fetal calf serum, 1% penicillin-streptomycin, and 10 μg/ml insu-
lin and transferrin. Transfected Bix3 cell lines were maintained in the
same medium but with 200 μg/ml geneticin. Before RNA isolation,
the cells were serum-starved for 48 hours. Serum-starved conditioned
media were obtained for the parent and Bix3 transfectants and were
concentrated 100-fold using the 10,000 MW cutoff Centriprep 10 con-
centrators (Amicon, Beverly, MA). Before the invasion assay, the cells
were grown in the normal medium but with 1% NuSerum (BD Bio-
sciences, New Bedford, MA) instead of 1% fetal calf serum for 24 hours
to limit the presence of protease inhibitors. The invasion assay was car-
ried out in 1% NuSerum for the same reason.
For the experimental model of 3′UTR knockdown of CSF-1 ex-
pression, we used the spontaneously immortalized normal ovarian
surface epithelial cells (NOSE.1), which secrete low levels of CSF-1
and are nontumorigenic [9], and the Hey ovarian carcinoma cell
line, which, in contrast, expresses high levels of CSF-1 and exhibits
virulent tumor growth in vitro [9,10,13]. Overexpression of 3′UTR
sequences as knockdown of CSF-1 was carried out in these cells to capi-
talize on these two extremes of CSF-1 expression and tumorigenicity.
Transfection
Cells were cotransfected using Lipofectamine (Gibco BRL,
Gaithersburg, MD) with p3ACSF69 (American Type Culture Col-
lection, Rockville, MD) [14], an expression vector containing the
4.0-kb human CSF-1 cDNA sequence, and pWLneo (Stratagene,
La Jolla, CA), which contains the neomycin resistance gene and al-
lows for selection by treatment with geneticin. Cells were plated onto
100-mm plates and allowed to grow to 60% confluence. Cells were
rinsed twice with PBS and then overlaid with a cocktail of the
p3ACSF69, pWLneo, and Lipofectamine in Dulbecco’s modified
Eagle’s medium. After a 3-hour or an overnight incubation, the trans-
fection cocktail was removed, and cells were fed with normal media.
After a 48-hour recovery period, geneticin (Gibco BRL) was added
into the media. Several colonies expressing neomycin resistance were
isolated and grown. CSF-1 secretion was measured by CSF-1 sand-
wich enzyme-linked immunosorbent assay (ELISA) of conditioned
media of Bix3 parent and transfected cells, with the highest four
transfected clones secreting CSF-1 selected for further characteriza-
tion. One neomycin-resistant clone that did not secrete any detect-
able CSF-1 served as a negative control.
CSF-1 Sandwich ELISA
Secreted CSF-1 protein levels were measured in the conditioned
medium by CSF-1 sandwich ELISA as described previously [10]
and were reported as picograms of CSF-1 per milliliter ± SEM.
Isolation and Analysis of Total Cellular RNA
Total cellular RNA was extracted from Bix3 parent and transfected
cells using the guanidium cesium chloride gradient method [15].
The RNA (20 μg per well) were electrophoresed in a 1% agarose-
formaldehyde gel and were downward transferred onto Gene Screen
Plus (New England Nuclear, Boston, MA). The Northern blots were
then hybridized to a 32P-labeled 180-bp exon-1 c-fms probe created
by EcoR1 and Hind3 digestion of a pBluescript construct into which
exon 1 had been cloned [16]. The blots were washed to a high strin-
gency of 0.1× SSC at room temperature, twice for 30 minutes each
with c-fms transcript visualized by autoradiography.
Run-off Transcription Assay
Assays of CSF-1 transcription rate in the nuclei of Bix3 parent and
clones were performed as described previously [17], except that the
linearized plasmid containing the 779-bp CAT cDNA (pMSGCAT;
Amersham Pharmacia, Piscataway, NJ), was included as the nega-
tive control.
Invasion Assay
The Membrane Invasion Culture System was used to measure,
quantitatively, the degree of invasion of Bix3 parent, Hey parent,
NOSE.1, and Bix3 transfected CSF-1–overexpressing clones as a corre-
late of the phenotypic behavior expected from these respective tumor
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cell lines, as described previously [9,10,18,19]. For some experiments,
cells were treated with vehicle in the absence or presence of 2 to 10 μM
B428, a potent synthetic uPA inhibitor (kindly provided by B.A.
Littlefield, Eisai Research Institute, Andover, MA) [20], and invasion
was measured through an extracellular matrix barrier. B428 (1 mM)
in 10% dimethyl sulfoxide served as the stock solution. Parent or trans-
fected cells, 1 × 105, were seeded onto 10-μm pore filters coated with a
human defined matrix containing 50 μg/ml human laminin, 50 μg/ml
human collagen IV, and 2 mg/ml gelatin in 10 mM acetic acid. The
results are reported as mean percent invasion ± SEM. Four independent
experiments were performed.
Assay of Urokinase Activity
Urokinase activity was measured at the cell surface of Bix3 parent
cells and transfectants as described [21]. A total of 1.5 × 105 cells per
well in complete medium were plated in 96-well plates. The next
day, they were 85% confluent. After washing the wells with PBS–
0.1% BSA, each well was incubated with 37.5 μg of the chromogenic
synthetic uPA substrate S-2444 (Sigma, St. Louis, MO) at 37°C.Wells
without cells that had received complete medium only served as the
negative control. Absorbance at 405 nm was measured after 6 hours
in an ELISA plate reader, with results reported as A405 ± SEM. Five
independent experiments were performed.
Adhesion and Motility Assays
The Membrane Invasion Culture System was also used to quantita-
tively measure the degree of adhesion of the Bix3 parent, Hey parent,
NOSE.1, and Bix3 transfected clones onto a filter coated with human
defined matrix as above. The cells that had implanted on the matrix-
coated filter after 2 hours were fixed and stained in 0.5% crystal violet
in 25% methanol, and the filters were dried overnight. Crystal violet
staining was then extracted from each filter containing adherent cells
by incubating in 0.1 M sodium citrate in 50% ethanol twice, and
absorbance was read at 585 nm [18,22]. The results were reported
as A585 ± SEM. Four independent experiments were performed.
Similarly, directed motility assays of Bix3 parent and transfected cells
were performed using the Membrane Invasion Culture System, as de-
scribed previously [18]. Fibronectin (25 μg/ml; Fisher, Pittsburgh, PA)
was used as a chemoattractant in the lower wells, above which uncoated
10-μm pore filters were placed. The results were reported as mean per-
cent motility ± SEM. Five independent experiments were performed.
c-fms Antisense Therapy
The effect of antisense oligomer therapy for knockdown of the re-
ceptor for the CSF-1 ligand endogenously expressed in our clones was
also studied. Invasion, adhesion, andmotility assays were performed in
the presence of a phosphorothioate-modified 18-mer directed toward
the c-fms translation initiation site (5′CTGGGCCCATGGCCTCGG′3)
and were compared to those of a scrambled 18-mer nonsense control
(5′ACCCCGGTCCTCGGGGTG′3). Bix3T8.2 cells were transiently
transfected with 2.5 to 10 μM of antisense or scrambled oligomers
along with Lipofectamine plus reagent (Gibco BRL) with a dose-
response curve generated for the individual concentrations after mea-
suring invasion after 72 hours. An optimal concentration of 7.5 μM
was initially ascertained from invasion assays using increments of
2.5 μM (data not shown). Three independent experiments were then
performed using this ideal oligomer concentration for each of the in-
vasion, adhesion, and motility in vitro tumor assays. Cells were treated
for 72 hours with oligomers before performing the in vitro assays.
3′UTR Knockdown of CSF-1
3′UTR sequences are known to regulate most posttranscriptional
events and can dramatically alter cellular function by regulating gene
expression [23–25]. The 144nt AU-rich element of 3′UTR of the
4-kb CSF-1 described previously [9,26] cloned in a pCMV-Tag1 vector
(Stratagene, Santa Clara, CA) was used for stable transfection of the
CSF-1–expressing Hey ovarian carcinoma cell line. The vector alone
served as a negative control for invasion and in vivo tumor studies in
nude mice. Expression of excess 144nt 3′UTR CSF-1 sequences was
confirmed in the clones by competitive reverse transcription–polymerase
chain reaction, using forward T3 and reverse T7 primers to amplify
the cloning site within the pCMV-Tag1 vector, with the empty vec-
tor as an internal template for competition. The competitive reverse
transcription–polymerase chain reaction was performed as described
previously [17].
Intraperitoneal Tumor Growth in Nude Mice
Tumor burden was measured in vivo 45 days after tumor cell in-
oculation of Bix3T8.2 CSF-1–overexpressing transfectants or the
Bix3T3.1 non–CSF-1–expressing control cells into the peritoneal
cavity of 6- to 8-week-old female NIH athymic NCr-nu mice (10
per condition). The period was chosen so that the extent of subclin-
ical disease could be measured, i.e., before abdominal distension or
any evidence of clinically apparent disease. It has been previously
shown [2] that Bix3 parent cells metastasize widely only after 60 days
after tumor cell transplantation. On day 0, 1 × 106 cancer cells in
serum-free medium were injected i.p. into each mouse. All the mice
appeared healthy at the time of euthanasia on day 45. The extent of
macroscopic and microscopic metastases as well as microscopic evi-
dence for invasiveness was assessed and compared between the two
groups. Specimens from ovary, uterus, mesovarium, mesometrium,
omentum, mesentery, lymph nodes, bowel, spleen, pancreas, liver,
portal region, kidney, diaphragm, mediastinum, and lung were col-
lected, fixed in 10% phosphate-buffered formalin, and processed for
standard histologic analysis.
Similar i.p. inoculation of 3′UTR knockdown Hey cells and con-
trols was performed in the NIH athymic NCr-nu mice.
Statistical Analysis
Paired or unpaired t tests, or Kruskal-Wallis one-way analysis of vari-
ance on ranks was applied, as appropriate, using Sigma Stat (Jandel
Scientific Corp., San Rafael, CA). A P value of <.05 was considered
statistically significant.
Results
Characterization of CSF-1 Clones
Secreted CSF-1 protein levels. Bix3 parent cells secrete relatively
small amounts of CSF-1 into conditioned media compared with other
more invasive ovarian cancer cell lines [10]. To initially screen Bix3
transfectants that were selected by neomycin resistance, we evalua-
ted levels of secreted CSF-1 from conditioned media. From four trans-
fected clones that produced similar magnitudes of elevated CSF-1
secretion, we selected one representative CSF-1–producing clone,
Bix3T8.2, which produced a 72-fold increase (360 ± 3.1 pg/ml) of
secreted CSF-1 when compared to Bix3 parent cells (5.0 ± 0.2 pg/ml).
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This representative Bix3 T8.2 clone also provided the greatest amount
of cell surface urokinase activity (OD A405 = 0.298 ± 0.008) com-
pared with the Bix3 parent control (OD A405 = 0.136 ± 0.003),
P < .001, as one would expect using uPA as a surrogate marker for
CSF-1 secretion and owing to the stimulatory effect of exogenous
CSF-1 on the extent of uPA [10]. One neomycin-resistant clone
(Bix3T3.1) secreted no detectable CSF-1 (0.0 ± 0.0 pg/ml) and was
chosen to serve as a negative control.
CSF-1 gene transcription. To ascertain whether the increased pro-
tein production of secreted CSF-1 was a direct result and in propor-
tion to enhanced CSF-1 gene expression in Bix3T8.2 cells, as we
would expect in this experimental model of stable transfection, we
quantitated the resultant rate of CSF-1 gene transcription from nu-
clear run-off assays. A 26.9-fold increase in CSF-1 gene transcription
was demonstrated in the nuclei of Bix3T8.2 CSF-1–overexpressing
cells, compared to that in the nuclei of Bix3 parent cells (Figure 1).
Relative to the Alu control, which serves as a measure of global tran-
scription and is increased in the Bix3 parent compared to the Bix3T8.2
cells, CSF-1 gene transcription is increased 57.2-fold in the Bix3T8.2
nuclei. The pMSGCAT vector sequences serve as the negative con-
trol for gene transcription. Thus, CSF-1 overexpression seen in the
Bix3T8.2 clone–transfected clones seems to be largely on the basis of
enhanced CSF-1 gene transcription because the increase in CSF-1
mRNA transcription and secreted protein is of a similar magnitude.
Assessment of Bix3T8.2 Tumor Phenotype
Invasion. The degree of invasion through an extracellular matrix
barrier by the CSF-1–overexpressing transfectant Bix3T8.2 was com-
pared with that of controls where CSF-1 expression and ability for
invasion had been quantitatively measured. It has previously been
shown that the Bix3 parent cells are weakly invasive through both
a Matrigel and a human defined matrix barrier [10]. We confirm
our observation that Bix3 cells are minimally invasive (1.12 ±
0.14% invasion) and demonstrate that the stably transfected Bix3T3.1
cells, which do not express CSF-1, are similarly (P > .05) minimally
invasive through the human defined matrix (0.79 ± 0.16% invasion).
Thus, stably transfected Bix3 cells, which express only the neomycin
resistance gene, do not exhibit enhanced invasiveness. In contrast, we
find that with the CSF-1–overexpressing transfectant Bix3T8.2 line,
the degree of invasion was significantly increased (P < .001) by almost
9-fold (9.73 ± 1.22% invasion), when compared to parent cells, or by
12.3-fold (P < .001), when compared to the neomycin-resistant trans-
fectant control (Figure 2).
To provide evidence that this enhanced invasiveness occurring in
the CSF-1–overexpressing Bix3T8.2 cell line was a result of the uro-
kinase system previously described [10], we used the potent synthetic
uPA inhibitor B428. B428 [20] has been shown to inhibit cell sur-
face uPA and surface uPA–mediated cellular degradative functions.
Compared to vehicle or untreated controls, we show a clear dose-
response inhibition of invasiveness in these cells of up to 2.8-fold by
increasing doses of B428 from 2 to 10 μM (Figure 3; P = .002). There
is no significant effect of the vehicle on invasiveness, compared to un-
treated cells. Thus, the significant increase in cell surface uPA activity
that we demonstrated by CSF-1 seems to contribute in part to the en-
hanced invasiveness exhibited by Bix3T8.2 cells.
Adhesion and motility. The correlation of secreted CSF-1 circulat-
ing in serum and ascites with advanced metastatic disease suggests
induction of a metastatic cascade after the initial tumor invasion.
The ability of the Bix3T8.2-transfected cells to adhere to a mem-
brane coated with human defined matrix was studied in comparison
with the Bix3T3.1 non–CSF-1–expressing transfectant line. As seen
in Figure 4, the BixT8.2 cells exhibited almost a two-fold increase
(P = .007) in the percentage of cells adhering to the membrane
Figure 1. Analysis of gene transcription in nuclear run-off of
Bix3T8.2 CSF-1–overexpressing cells and Bix3 parent cells. The
32P-labeled nuclear RNA was hybridized to linearized plasmids
containing the 4-kb CSF-1, 3.1-kb Alu, or 0.8-kb CAT sequences,
immobilized on a nitrocellulose filter.
Figure 2. Degree of invasion of parent and transfected (Bix3T8.2)
cells through a human extracellular matrix barrier. Bix3 parent and
transfected (Bix3T3.1 and Bix3T8.2) cells invading through the hu-
man defined matrix–coated filter after 48 hours were stained,
counted, and expressed as mean percent invasion ± SEM of the
total number of cells loaded into the upper chamber. Antisense
treatment of Bix3T8.2 cells in the presence of 7.5 μM of an 18-
mer directed antisense toward the c-fms translation initiation site
or its scrambled oligomer control is also shown (shaded half). Sig-
nificant increase in the invasiveness of the overexpressing
Bix3T8.2 clone is seen (P < .001) compared with control cells
(Bix parent and Bix3T3.1), which is significantly inhibited by anti-
sense treatment (P < .001).
Neoplasia Vol. 11, No. 2, 2009 CSF-1 and Metastasis in Ovarian Cancer Toy et al. 139
(66.9 ± 6.7%) compared with the parental Bix3 cells (35.8 ± 2.8%)
and the negative Bix3T3.1 control (47.3 ± 2.3%).
Further study of the metastatic potential of these Bix3T8.2 cells
was performed using the same chamber assay now with fibronectin
as a chemoattractant to determine directed motility of the tumor cells
through the membrane. As seen in Figure 5, the BixT8.2 cells exhib-
ited an approximately six-fold increase (P < .001) in the percentage of
cells (18.0 ± 1.9%) migrating through the membrane in the absence
of matrix components to the lower chamber compared with the pa-
rental cells (3.1 ± 0.4%) and the Bix3T3.1 control (3.7 ± 0.3%).
Again, a highly significant statistical difference was seen between
the groups (P < .001). No significant differences were seen in either
adhesion or motility assays between the parental negative control and
the transfectant Bix3T3.1 control.
In vivo metastasis. We thus have shown that endogenous CSF-1
overexpression in ovarian cancer cells leads to increased invasiveness,
adhesion, and motility, all crucial factors in the metastatic cascade.
We next studied the role for CSF-1 overexpression directly on the
metastatic phenotype of ovarian cancer cells, in nude mice.
Four of the 10 control mice bearing non–CSF-1–expressing
Bix3T3.1 cells had no pathologic evidence for cancer. The rest had
only one to three foci of 0.5- to 1-mm peritoneal implants. In con-
trast, 9 of the 10 mice bearing CSF-1–overexpressing Bix3T8.2 cells
had several, up to 20, 2- to 5-mm implants throughout the perito-
neal cavity. The remaining mouse had evidence for extensive lymph
node metastases. On microscopic examination of the 6 of the 10 mice
that developed tumor from the non–CSF-1–expressing Bix3T3.1 ovar-
ian cancer cells, 3 had evidence for multifocal peritoneal disease and
the other 3 had evidence for unifocal peritoneal disease. Their nodules
were well circumscribed, were enclosed in a fibrous capsule, and were
accompanied by a nonsuppurative inflammatory infiltrate. None of
these 6 mice had any evidence for lymph vascular space invasion,
lymph node metastasis, invasion of the ovary or any other organ, trans-
diaphragmatic invasion, or distant metastasis (Table 1).
Figure 4. Degree of adhesion of Bix3 parent and transfected cells
2 hours after seeding on a human defined matrix. Bix3T3.1 cells
served as the non–CSF-1–expressing transfectant control. Absor-
bance was measured at 585 nm after the extraction of crystal vi-
olet from stained adhered cells and expressed as mean A585 ±
SEM (bars). A two-fold increase in adhesiveness was seen with
Bix3T8.2 over controls (P = .007).
Figure 5. Degree of fibronectin-directed motility of Bix3 parent
and transfected cells. Bix3T3.1 cells served as the non–CSF-1–
expressing transfectant control. The cells that moved from the
upper to the lower fibronectin-containing chamber after 6 hours
were stained, counted, and expressed as mean percentage of
the total number of cells loaded into the upper chamber ± SEM
(bars). Effect of antisense treatment of cells in the presence of
7.5 μM of an 18-mer directed antisense toward the c-fms transla-
tion initiation site or its scrambled oligomer control for 72 hours is
also shown (shaded half). This difference in motility was highly,
statistically significant (P < .001).
Figure 3. Degree of invasiveness through a human defined matrix
of CSF-1–overexpressing Bix3T8.2 cells in the presence or ab-
sence of B428, a potent uPA inhibitor (2-10 μM). The cells that
invaded through the human defined matrix–coated filter after
48 hours were stained, counted, and expressed as mean percent
invasion ± SEM of the total number of cells loaded into the upper
chamber with significant inhibition of invasiveness in a dose-
response fashion seen with B428 (P = .002).
Table 1. Metastasis in Nude Mice Related to CSF-1.
Tumor Site Transfectant Cell Lines
Bix3T3.1 (N = 10) Bix3T8.2 (N = 10)
Peritoneal seeding 6 9
Visceral ovarian involvement 0 4
Lymph nodes 0 8
Distant lung (including transdiaphragmatic invasion) 0 4 (5)
Total number of mice exhibiting tumor 6/10 10/10
Widely metastatic disease was seen after intraperitoneal injection of CSF-1 overexpressing Bix3T8.2
cells compared to control Bix3T8.2.
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In marked comparison, all 10 mice bearing the CSF-1–overexpressing
Bix3T8.2 ovarian cancer cells had evidence for either extensive peri-
toneal spread of tumor and/or extensive lymph node metastases
(Table 1). Further, organ invasion and distant metastasis were common
findings. The portal region was involved by tumor in five mice, visceral
invasion of the ovary in four mice (visceral invasion of the liver and
pancreas was less frequently observed), transdiaphragmatic invasion in
three mice, lymph node invasion in eight mice (most commonly af-
fected lymph nodes were mesenteric, portal, inguinal, mediastinal,
and rarely submandibular; lymph vascular space invasion was present
in animals with extensive tumor infiltration), and lung metastases in
four mice. These metastases were unencapsulated, invasive, and did
not evoke an inflammatory infiltrate. Representative examples of differ-
ences in the microscopic appearance of tumor developing after i.p. in-
jection of Bix3T3.1 versus T8.2 cells are depicted in Figure 6.
Therefore, we have demonstrated a marked increase in i.p. tumor
burden, lymph node and organ invasiveness, and distant metastasis,
resulting from CSF-1–overexpressing transfectants when compared
to their non–CSF-1–expressing controls. Further, our data suggest
an effect of CSF-1 on tumorigenicity, in that 40% of mice bearing
non–CSF-1–expressing cells did not develop any tumors, in compar-
ison to the virulence of tumors developing in 100% of mice bearing
Bix3T8.2 CSF-1–overexpressing cells.
Establishment of the Autocrine Loop Pathway as a Mechanism
for CSF-1 Transformation of Bix3 Ovarian Carcinoma Cells
Knockdown of the CSF-1 receptor. Confirmation of CSF-1 auto-
crine stimulation in the Bix3T8.2 tumor cells was further provided
by the interruption of the autocrine loop using antisense therapy di-
rected against the CSF-1R. Northern blot analysis of antisense-treated
Bix3T3.1 cells is shown in Figure 7. Successful down-regulation of
c-fms proto-oncogene expression is seen compared with the nonsense
oligomer treatment and Lipofectamine alone. Similar results were
demonstrated in Bix3T8.2 cells (data not shown).
With this antisense inhibition of the c-fms proto-oncogene encod-
ing the CSF-1R, we performed parallel experiments to study invasion,
adhesion, and motility in the CSF-1–overexpressing transfectant
Figure 6. Comparison of extent and histologic characteristics of tumor metastases between nude mice bearing the control Bix3T3.1 (A,
C) or CSF-1–overexpressing Bix3T8.2 (B, D) ovarian cancer cells. (A) Bix3T3.1. Omentum. Nodular neoplastic masses (asterisks) are en-
capsulated by fibrous tissue and are accompanied by a (nonsuppurative) inflammatory infiltrate (thick arrow). Single neoplastic cells are
seen infiltrating the surrounding fibrous tissue (thin arrow). Bar, 200 μm. (B) Bix3T8.2. Mesometrium (mouse equivalent of peritoneum
supporting the ovary) metastasis. Neoplastic nodules are unencapsulated and do not evoke an inflammatory reaction, indicating more
rapid metastasis than in (A). Bar, 200 μm. (C) Bix3T3.1. Diaphragm. Metastatic cells are limited to a heavily encapsulated nodule located
on the peritoneal surface of the diaphragm. Bar, 200 μm. (D) Bix3T8.2. Diaphragm. Large neoplastic masses extend from the peritoneal
surface (asterisk) through the diaphragm to the pleural surface (arrow). Bar, 500 μm.
Figure 7. Northern blot analysis of antisense treatment of c-fms
showing knockdown of gene expression. The blot was hybridized
to a 32P-labeled 180-bp exon-1 c-fms probe created by EcoR1 and
Hind3 digestion of a pBluescript construct into which exon 1 had
been cloned [17]. Autoradiography reveals decreased c-fms tran-
script by antisense treatment.
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Bix3T8.2 cell line. Shown in the shaded area of Figure 2, the antisense
treatment of the CSF-1–overexpressing Bix3T8.2 cells produced approx-
imately a 3-fold reduction of the percent invasion (3.37 ± 0.42%)
compared with the untreated Bix3T8.2 cells and a 3- to 3.5-fold
reduction compared with the Lipofectamine- (10.5 ± 1.4%) and
nonsense- (11.3 ± 1.7%) treated Bix3T8.2 cells, respectively (P <
.001). Of note, there was no significant difference between the in-
vasiveness of Bix3T8.2 cells with antisense c-fms treatment and
Bix3T3.1 control, or Bix3 parent cells. Similar results were seen in
the constitutively CSF-1–overexpressing parental Hey ovarian carci-
noma cell line with a two-fold reduction in invasion (5.83 ± 1.01%)
observed with antisense treatment compared with the nonsense con-
trol group (10.44 ± 0.92%). In a parallel adhesion assay using
Bix3T8.2 cells, almost a three-fold decreased adhesion was seen (P =
.011) using antisense therapy compared to the application of nonsense
oligomers (data not shown). The decrease in motility translated into an
approximate 2-fold reduction, again, in the antisense treatment group
(10.3 ± 1.2) compared with the untreated parental cells and a 1.5-
to 1.7-fold decrease compared to the nonsense- and Lipofectamine-
treated groups (P < .001; Figure 5, shaded ). There were no significant
differences seen between the negative control groups within the var-
ious assays. Thus, interrupting the autocrine loop by antisense target-
ing of the CSF-1R resulted in a substantial inhibition of the invasive,
motile, adhesive ovarian cancer phenotype.
3′UTR knockdown of CSF-1. To further study the interruption
of the autocrine loop but at the feedback level of secreted CSF-1 pro-
tein, we introduced an expression plasmid containing cDNA corre-
sponding to the 144nt AU-rich fragment of the 3′UTR of the 4-kb
CSF-1 mRNA by stable transfection into the notably tumorigenic
and virulent CSF-1–overexpressing Hey ovarian carcinoma cell line
[10,14], as well as the spontaneously immortalized NOSE.1 cells [9].
Most posttranscriptional events are regulated by 3′UTR sequences.
The 3′UTRs have the capacity to dramatically alter cellular function
by regulating gene expression [23–25]. These actions of 3′UTR
RNA are thought to be modulated by RNA protein binding. We
focused on this 144nt AU-rich element [9,26] because we had
previously defined this region as critical for regulatory protein bind-
ing of the 4-kb CSF-1 transcript. In fact, we have previously shown
that excess 144nt AU-rich sequences can downregulate endogenous
CSF-1 mRNA levels [9]. Further, we have demonstrated that GAPDH
protein binding with this 3′UTR element promotes CSF-1 mRNA
stability and that silencing GAPDH decreases secreted CSF-1 levels
in NOSE.1 and Hey cells [26]. Delivery of excess 3′UTR sequences
seems to act by sequestering stabilizing proteins such as GAPDH, re-
sulting in the down-regulation of gene expression.
We first studied the effect of excess 144nt 3′UTR CSF-1 se-
quences on secreted CSF-1 levels. More than a two-fold reduction
(P < .001) in the secretion of CSF-1 was seen from parental Hey cells
(791 ± 26 pg/ml) compared to the 3′UTR expressing transfectant
(387 ± 19 pg/ml), and this mirrored the reduction seen in the spon-
taneously immortalized NOSE.1 control cell line, which was also on
the order of a 1.5- to 2-fold reduction compared to parental- and
vector-alone controls (data not shown).
With CSF-1 levels reduced by half from the parental cells, we as-
sessed tumor phenotype using both in vitro invasion/motility assays
and the measurement of in vivo metastasis. First, a baseline compari-
son of our transfectant-negative control Bix3T3.1, immortal NOSE.1-
negative control, the CSF-1–overexpressing Bix3T8.2 transfectant,
and positive control Hey parental cells was made for both invasion
and motility. A 10-fold increase in the degree of invasion was seen
with Hey cells compared to NOSE.1 cells with an almost three-fold
increase in motility seen (Figure 8). Hey cells provided the extreme
range of invasiveness and motility in this in vitro model (P < .001;
Figure 8). With the overexpression of the 144nt 3′UTR CSF-1 se-
quence in NOSE.1 and Hey cell lines, a significant reduction in inva-
siveness through human defined matrix compared to parent or vector
controls was seen in both the NOSE.1 cells (2.45-fold) and the Hey
cell line (3.25-fold), respectively, with no significant difference de-
tected between vector and parent controls. In Hey cells, the percent
invasion of parent cells, 55.5 ± 1.3%, was reduced to 17.1 ± 0.8%
(P < .001) in the presence of excess 144nt CSF-1 sequences. The
magnitude of reduction of invasiveness of these cells was in line with
the level of reduction of secreted CSF-1 by excess 144nt 3′UTR
AU-rich CSF-1 sequences. These results provided a basis for our sub-
sequent experiments in nude mice. Having afforded the most ex-
treme range of tumor invasion and motility, we used the Hey cells
(NOSE.1 cells not being tumorigenic [9]) for our nude mice experi-
ments with 10 mice inoculated in each group. Only 3 of the 10 mice
in the 144nt AU-rich 3′UTR CSF-1–overexpressing group mani-
fested any evidence of tumor take by day 45 after inoculation, and
these lesions were inoculation site tumors only. This was compared
to the 90% of the animals in the untreated Hey group that developed
gross evidence of tumors within this time frame. Seven of the 10 an-
imals in the untreated Hey group developed inoculation site tumors,
6 animals developed intra-abdominal tumors, 3 animals showed
lymph node invasion, and 2 showed distant spread of tumor to other
organ sites (Table 2). There were little differences seen in the pattern
of spread between control Hey cells expressing vector sequences and
the parent Hey cells (Table 2). This reduction in both tumorigenesis
Figure 8. Baseline comparison of motility and invasion of cells used
for in vivo studies. Transfected Bix3 and parental NOSE.1 and Hey
ovarian carcinoma cells were studied in preparation for i.p. injection
into nude mice. An increase of approximately 10-fold greater inva-
siveness was seen with Hey cells over the nonvirulent NOSE.1 cell
line with three-fold greater motility seen in vitro (P < .001).
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and metastatic potential provided additional evidence of the etiologic
role of CSF-1 in the progression of ovarian cancer.
Discussion
The prognostic value of CSF-1 in predicting outcome in epithelial
ovarian cancer has been recognized [1,4,5]. This cytokine, normally
associated with monocyte/macrophage proliferation and placental tro-
phoblast implantation, is also present in cancers of varying origin and
is prognostic of invasive tumors and poor outcome. Most, if not all,
ovarian cancer cell lines express CSF-1, with the degree of expression
correlated with invasive capacity [2,10]. In this report, we describe our
finding that Bix3 ascitic human ovarian cancer cells transfected with
the 4.0-kb CSF-1 cDNA sequences were transformed into a signifi-
cantly more invasive, motile, and metastatic counterpart, which largely
explains, for the first time, the poor prognosis associated with tumors
that overexpress c-fms and CSF-1 in their metastases [1].
Modulation of CSF-1 levels in the Bix3 parent cells was achieved at
the gene and protein levels and correlated with tumor phenotype. The
low level of CSF-1 expression in these parent cells provides a baseline for
both CSF-1 secretion and a tumor behavior on which experimentally
enhanced CSF-1 gene transcription can elevate levels of endogenously
secreted protein to mimic the pathologic levels found in clinical stud-
ies [4]. In contrast, the high-level CSF-1–expressing Hey ovarian cancer
cell line provides a benchmark for CSF-1 secretion and extreme invasive-
ness and virulence of tumorigenicity [9,10] (Figure 8 and Table 2).
This increase in CSF-1 expression (a 72-fold higher gene tran-
scription corresponding to a 57-fold increase in secreted CSF-1 pro-
tein production) in the Bix3T8.2 cells resulted in a highly significant
increase in the invasiveness, adhesion, and motility observed in vitro
(Figures 2, 4, and 5). It is acknowledged that no single in vitro test
to assess invasion or motility is sufficient for clinical translation and
that the in vitro models used here lacked the advantages of video-
microscopy and three-dimensional modeling used in other models
[27,28]. However, clinical evidence of increased tumorigenicity and
of its virulence is provided from the in vivo inoculation of nude mice
through i.p. injection. This level of tumor take and metastasis is
comparable to the baseline tumorigenicity of the aggressive Hey cell
line (Table 2). Because the peritoneal circulation is the main route of
spread through this route of inoculation, the ability of the overex-
pressing CSF-1 clone Bix3T8.2 to produce widespread metastasis
that is diverse and infiltrative lends credence to the effect of CSF-1
overexpression on the phenotype observed in vivo.
It follows that therapeutic intervention at the mRNA and protein
levels of expression should inhibit CSF-1–induced transformation of
cells and diminish both invasiveness and metastatic potential. Suc-
cessful down-regulation of CSF-1 mRNA transcript and secreted
protein through interference with the stabilization of the mRNA
transcript by silencing of the CSF-1 RNA binding protein, GAPDH
[26], is evidence that manipulation of posttranscriptional gene ex-
pression is possible and may prove to affect tumor phenotype. Here,
we have used the 144nt AU-rich element of 3′UTR CSF-1, which
we have shown to be a target for binding by regulatory proteins, for
competition with endogenous 3′UTR CSF-1 mRNA to sequester
binding partners that would otherwise cause mRNA stabilization,
such as GAPDH. AU-rich elements are the best characterized among
the variety of signals that dictate mRNA decay.
The effect of overexpression of this 144nt sequence from the CSF-1
transcript is proportionately reflected by the two-fold decrease in se-
creted CSF-1 levels, resulting in a 2.5- to 3-fold reduction in invasive-
ness. This then resulted in a disproportionate and dramatic reduction
in in vivo tumorigenicity and invasive metastasis (Table 2), which may
reflect the critical involvement of the tumor microenvironment on the
resulting tumor phenotype. Notably, in our stable transfection model,
those metastatic foci arising from ovarian cancer cells not expressing de-
tectable CSF-1 (Bix3T3.1 cells) elicited an intense inflammatory infil-
trate and were well encapsulated in a fibrous capsule. This is in striking
contrast to the invasive and extensive nature of themetastatic foci arising
from the CSF-1–overexpressing Bix3T8.2 ovarian cancer cells, which
were not associated with an inflammatory reaction (Figure 6). Interest-
ingly, this in vivo data reflecting the potential protective role of stromal
infiltration in the ovarian cancer is in line with our observations in hu-
man ovarian cancer specimens of stromal CSF-1 expression portending
an improved clinical outcome [1]. This contrasts with the well-accepted
tumor-promoting role of tumor-associated macrophages expressing
CSF-1 in breast cancer [29]. It is also important to recognize that the
effect of excess 144nt AU-rich 3′UTR CSF-1 sequences is not specific
to the regulation of endogenous CSF-1 expression and, in sequestering
other regulatory RNA binding proteins, could affect the regulation of
other targets affecting tumor phenotype. Current and developing in vivo
siRNA [30] and miRNA technologies may afford a more efficient and
selective targeting of the CSF-1 transcript [31].
Although decreases in secreted CSF-1 protein availability translate
into an inhibition in the invasive and metastatic phenotype, disrup-
tion of the receptor/ligand autocrine loop provides additional steps to
prevent the transformation of otherwise indolent Bix3 parental cells.
When stably transfected with the CSF-1 transcript, the degree of
mRNA expression and the increased protein production in parental
Bix3 correlate with a significantly higher number of invasive cells
in vitro and metastatic lesions, in vivo (Figure 2 and Table 1). Anti-
sense targeting of the CSF-1R encoded by c-fms results in disruption
of this autocrine loop established by the endogenous secretion of
CSF-1 from the Bix3T8.2 transfectants, resulting in a significant in-
hibition of the highly aggressive ovarian cancer phenotype.
Therapeutic application of technologies directed against this auto-
crine pathway has begun to show promise. The obstacles associated with
the delivery of such antisense oligomers have been recently addressed
[32]. Elucidation of downstream signaling pathways of CSF-1R [33–
36] and other tyrosine kinase receptors has also been investigated; how-
ever, despite a number of agents that have been developed, which target
c-fms (e.g., vatalanib, ABT869, CYT645, Ki20227), to date, none have
been tested in ovarian cancer patients [37]. One Food and Drug
Administration–approved drug imatinib, which targets tyrosine kinase
receptor c-kit as well as c-fms, has failed to show activity in ovarian can-
cer [38]. Conversely, selective targeting of the uPA pathway, one of
the downstream mediators of CSF-1/CSF-1R action, has produced an
improvement in progression-free survival of ovarian cancer patients with
Table 2. 3′UTR Knockdown of CSF-1–Overexpressing Hey Cells in Nude Mice.







Peritoneal seeding 7 5 3
Visceral ovarian involvement 6 5 0
Lymph nodes 3 0 0
Distant lung (including transdiaphragmatic invasion) 2 2 0
Total number of mice exhibiting tumor 9/10 5/10 3/10
Treatment of Hey ovarian carcinoma cells using 3′UTR 144nt AU-rich fragment results in the
attenuation of tumor metastasis compared to parent and vector constructs.
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small tumor burden treated in a recent phase 2 trial of Å6 (an uPA
peptide that interferes with binding of uPA with uPAR) [37].
The model of autocrine stimulation represents a more biologically
relevant system by which ovarian cancers can stimulate invasion and
metastasis from sentinel lesions. Current use of microarrays to assess
tumor profiles provides only a single level of therapy that siRNA,
miRNA, or antisense treatment addresses. The synergistic strategy
of biologic therapy, which can also intervene to prevent the secretion
of the CSF-1 ligand in addition to targeting of the receptor, seems to
offer the most promising approach to interrupting the metastatic cas-
cade, which results from the establishment of the CSF-1 autocrine
loop. Currently available biologic therapies for other tyrosine kinase
receptor proteins recapitulate this syllogism.
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